

1616
RECEIVED
OCT 22 2002
TECH CENTER 1600
PATENTS
1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Agoston et al.)
Serial No. 09/939,208) Art Unit: 1616
Filed: August 24, 2001) Examiner: S.N. Qazi, Ph.D.
For: ANTIANGIOGENIC AGENTS)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of the listed items is enclosed.

Certificate

It is hereby certified, under Rule 97(e)(1), that each item of information contained in the accompanying Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC, 20231, on this 9th day of October, 2002.

Suzanne Seavello Shope
Suzanne Seavello Shope - Reg. No. 37,933

Serial No: 09/939,208

Filed 8/24/01

Supplemental Information Disclosure Statement

Page 2

not more than three months prior to the filing of the statement. A copy of the International Search Report is also attached.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Suzanne Seavello Shope

By: Suzanne Seavello Shope
Reg. No. 37,933

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 05213-0852 (43170-263550)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>						Complete if Known			
						Application No.		09/939,208	
						Filing Date		08/24/2001	
						First Named Inventor		Agoston et al.	
						Group Art Unit		1616	
						Examiner Name		S. N. Qazi, Ph.D.	
Sheet	2	of	10	Attorney Docket Number		05213-0852 (43170-263550)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴ (if known)				
	3	WO	00/07576	A2	ENDORECHERCHE, INC	02/17/2000	
	4	WO	00/10552	A2	Global Vascular Concepts, Inc.	03/02/2000	
	5	WO	00/66095	A2	Sterix Limited	11/09/2000	
	6	WO	00/68246	A1	Research Institute for Medicine and Chemistry Inc.	11/16/2000	
	7	WO	01/27132	A1	The University of Melbourne	04/19/2001	
	8	WO	01/85755	A1	Research Institute for Medicine and Chemistry Inc. and Marsden, John	11/15/2001	
	9	JP	39-5480	B	Teikoku Hormone Mfg. Co.		No
	10	GB	857,080		Syntex S.A.	12/29/1960	
	11	GB	857,081		Syntex S.A.	12/29/1960	
	12	SU	1240038	A1	A MED ONCOLOGY CENTRE (abstract only)	10/27/1996	
	13	DE	2 004 516		VEB Jenapharm	09/10/1970	
	14	WO	87/02367	A3	The Upjohn Company	04/23/1987	
	15	WO	88/08002	A1	The Upjohn Company	10/20/1988	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

RECEIVED
OCT 17 2002
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OCT 15 2002

PATENT & TRADEMARK OFFICE

<p>Substitute for Form 1449/A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/939,208
				Filing Date	08/24/2001
				First Named Inventor	Agoston et al.
				Group Art Unit	1616
				Examiner Name	S. N. Qazi, Ph.D.
Sheet	1	of	10	Attorney Docket Number	05213-0852 (43170-263550)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ²	Kind Code ³ (if known)			
	1	3,166,577		Ringold et al.	01/19/1965	
	2	3,562,260		De Ruggieri et al.	02/09/1971	

RECEIVED
OCT 17 2002
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO				Complete if Known		
				Application No.	09/939,208	
				Filing Date	08/24/2001	
				First Named Inventor	Agoston et al.	
				Group Art Unit	1616	
				Examiner Name	S. N. Qazi, Ph.D.	
Sheet	3	of	10	Attorney Docket Number	05213-0852 (43170-263550)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴				
	16	WO	98/32763	A1	SRI International	07/30/1998	
	17	WO	99/01142	A1	Hyal Pharmaceutical Corporation	01/14/1999	
	18	WO	99/33858	A3	SRI International	07/08/1999	
	19	WO	99/33859	A2	SRI International	07/08/1999	
	20	JP	41 000100 (XP-002200990)	A	Dainippon Pharmaceutical Co., Ltd. (abstract only)	01/07/1966	
	21	JP	42-928	B	DAINIPPON PHARM CO LTD (abstract only)	01/18/1967	

RECEIVED
OCT 11 2002
TECH CENTER 1600/2900

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

OCT 15 2002

PAPER
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/939,208
Filing Date	08/24/2001
First Named Inventor	Agoston et al.
Group Art. Unit	1616
Examiner Name	S. N. Qazi, Ph.D.

Sheet

4

of

10

Attorney Docket Number

05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	22	Author: ABOULWAFA et al. Publ: <u>Steroids</u>	Title: Synthesis and evaluation for uterotrophic and antiimplantation activities of 2-substituted estradiol derivatives Vol/Iss: 57	Pages: 199-204	Date: 04/1992
	23	Author: BLICKENSTAFF et al. Publ: <u>Steroids</u>	Title: SYNTHESIS OF SOME ANALOGS OF ESTRADIOL Vol/Iss: 46 (4,5)	Pages: 889-902	Date: 10/1985
	24	Author: BRANDI et al. Publ: <u>Calcif. Tissue Int.</u>	Title: Bone endothelial cells as estrogen targets (Abstract only) Vol/Iss: 53 (5)	Pages: 312-317	Date: 1993
	25	Author: BRUEGGEMEIER et al. Publ: <u>Journal of Steroid Biochemistry & Molecular Biology</u>	Title: 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits antiproliferative activity and alters tubulin dynamics Vol/Iss: 78	Pages: 145-156	Date: 2001
	26	Author: CRABBE, P. Publ: <u>Chem. Ind.</u>	Title: Cotton effect of the styrene chromophore (Abstract only) Vol/Iss: 27	Pages: 917-918	Date: 1969
OCT 17 2002	27	Author: DUBEY et al. Publ: <u>Biochemical and Biophysical Research Communications</u>	Title: Methoxyestriadiols Mediate the Antimitogenic Effects of Estradiol on Vascular Smooth Muscle Cells via Estrogen Receptor-Independent Mechanisms Vol/Iss: 278	Pages: 27-33	Date: 2000
RECEIVED	28	Author: EL-TOMBARY . Publ: <u>Arch. Pharm. Pharm. Med. Chem.</u>	Title: Synthesis, Uterotropic, And Antiuterotropic Activities of Some Estradiol Derivatives Containing Thiadiazole, Thiazoline, and Thiazolidinone Moieties Vol/Iss: 330 (9-10)	Pages: 295-302	Date: 1997

Examiner
SignatureDate
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

*Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

OCT 15 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No. 09/939,208

Filing Date 08/24/2001

First Named Inventor Agoston et al.

Group Art Unit 1616

Examiner Name S. N. Qazi, Ph.D.

Sheet

5

of

10

Attorney Docket Number

05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
	29	Author: EMONS et al. Publ: <u>FOCUS MHL</u>	Title: Modulation der hypophysaren Sekretion von Luteinisierendem Hormon (LH) durch Ostogene	Vol/Iss: 3	Pages: 221-228	Date: 1986
	30	Author: FANCHENKO et al. Publ: <u>Byull. Eksp. Biol. Med.</u>	Title: Characteristics of the guinea pig uterus estrogen receptor system (Abstract only)	Vol/Iss: 85 (4)	Pages: 467-470	Date: 1978
	31	Author: FRASER et al. Publ: <u>British Medical Bulletin</u>	Title: Angiogenesis and its control in the female reproductive system (Abstract only)	Vol/Iss: 56 (3)	Pages: 787-797	Date: 2000
	32	Author: GANDHI et al. Publ: <u>Journal of Indian Chem. Soc.</u>	Title: Mannich reaction of estrone	Vol/Iss: 39	Pages: 306-308	Date: 1962
	33	Author: HAHNEL et al. Publ: <u>Journal of Steroid Biochemistry</u>	Title: THE SPECIFICITY OF THE ESTROGEN RECEPTOR OF HUMAN UTERUS	Vol/Iss: 4	Pages: 21-31	Date: 1973
RECEIVED OCT 17 2002	34	Author: HE et al. Publ: <u>Bioorganic & Medicinal Chemistry Letters</u>	Title: NOVEL CYTOKINE RELEASE INHIBITORS. PART II: STEROIDS	Vol/Iss: 8	Pages: 2825-2828	Date: 1998
	35	Author: HEJAZ et al. Publ: <u>Journal of Medicinal Chemistry</u>	Title: Synthesis and Biological Activity of the Superestrogen (E)-17-Oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: X-ray Crystal Structure of (E)-17-Oximino-3-hydroxy-1,3,5(10)-estratriene	Vol/Iss: 42 (16)	Pages: 3188-3192	Date: 1999

Examiner
SignatureDate
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

OCT 15 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

10

Complete if Known

Application No. 09/939,208

Filing Date 08/24/2001

First Named Inventor Agoston et al.

Group Art Unit 1616

Examiner Name S. N. Qazi, Ph.D.

Attorney Docket Number 05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	43	Author: LIPPERT et al. Publ: <u>Life Sciences</u>	Title: The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells Vol/Iss: 67	Pages: 1653-1658	Date: 2000
	44	Author: LOOZEN et al. Publ: <u>J.R. Neth.Chem. Soc.</u>	Title: An approach to the synthesis of 7.β-amino estrogens (Abstract only) Vol/Iss: 102 (10)	Pages: 433-437	Date: 1983
	45	Author: LOVELY et al. Publ: <u>Journal of Medicinal Chemistry</u>	Title: 2-(Hydroxyalkyl)estradiols: Synthesis and Biological Evaluation Vol/Iss: 39	Pages: 1917-1923	Date: 1996
	46	Author: MACCARTHY-MORROGH et al. Publ: <u>Cancer Research</u>	Title: Differential Effects of Estrone and Estrone-3-O-Sulfamate Derivatives on Mitotic Arrest, Apoptosis, and Microtubule Assembly in Human Breast Cancer Cells Vol/Iss: 60	Pages: 5441-5450	Date: 10/01/2000
	47	Author: MICHEL et al. Publ: <u>Biochem. Pharmacol.</u>	Title: Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists (Abstract only) Vol/Iss: 36 (19)	Pages: 3175-3180	Date: 1987
OCT 17 2002 RECEIVED	48	Author: MORISAKI et al. Publ: <u>Chem. Pharm. Bull.</u>	Title: Steroids. I.1. Aromatization reaction of the cross-conjugated dienone system by Zinc 9. (Abstract only) Vol/Iss: 14 (8)	Pages: 866-872	Date: 1966
	49	Author: MUECK et al. Publ: <u>Journal of Clinical and Basic Cardiology</u>	Title: Angiogenetic and anti-angiogenetic effects of estradiol and its metabolites (Abstract only) Vol/Iss: 4 (2)	Pages: 153-155	Date: 2001

Examiner
SignatureDate
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

<p>Substitute for Form 1449/A/PTO</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/939,208
				Filing Date	08/24/2001
				First Named Inventor	Agoston et al.
				Group Art Unit	1616
				Examiner Name	S. N. Qazi, Ph.D.
Sheet	6	of	10	Attorney Docket Number	05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²	
	36	Author: HOLKER et al. Publ: <u>J. Chem. Soc. Perkin Trans.</u>	Title: The Reactions of Estrogens with Benzeneseleninic Anhydride and Hexamethyldisilazane	Vol/Iss:	1	Pages: 1915-1918	Date: 1982
	37	Author: HU, G. Publ: <u>Proceedings of the National Academy of Sciences, USA</u>	Title: Neomycin inhibits angiogenin-induced angiogenesis (Abstract only)	Vol/Iss:	95 (17)	Pages: 9791-9795	Date: 1998
	38	Author: IKEGAWA et al. Publ: <u>Biomed. Chromatogr.</u>	Title: Immunoaffinity extraction for liquid chromatographic determination of equilin and its metabolites in plasma (Abstract only)	Vol/Iss:	10 (2)	Pages: 73-77	Date: 1996
	39	Author: IRIARTE et al. Publ: <u>Tetrahedron</u>	Title: Steroids (XCIV). Synthesis of 2-methyl and 1,2-dimethyl estrogens (Abstract only)	Vol/Iss:	3	Pages: 28-36	Date: 1958
	40	Author: JAGGERS et al. Publ: <u>Journal of Endocrinology</u>	Title: Potent Inhibitory effects of steroids in an in vitro model of angiogenesis (Abstract only)	Vol/Iss:	150 (3)	Pages: 457-464	Date: 1996
OCT 17 2002 RECEIVED	41	Author: KOVACS et al. Publ: <u>Acta Phys.Chem.</u>	Title: Steroids. XXIII. Synthesis of 2- and 4-hydroxy and 2,4-dihydroxy derivatives of estrone and estradiol (Abstract only)	Vol/Iss:	19 (3)	Pages: 287-290	Date: 1973
	42	Author: KUREBAYASHI et al. Publ: <u>Oncology</u>	Title: Paradoxical hormone responses KPL-1 breast cancer cells in vivo: a significant role of angiogenesis in tumor growth (Abstract only)	Vol/Iss:	59 (2)	Pages: 158-165	Date: 2000


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OCT 15 2002



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/939,208
Filing Date	08/24/2001
First Named Inventor	Agoston et al.
Group Art Unit	1616
Examiner Name	S. N. Qazi, Ph.D.

Sheet

8

of

10

Attorney Docket Number

05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²	
	50	Author: NAMBARA et al. Publ: <u>Chem. Pharm. Bull.</u>	Title: Microbial transformation products derived from steriods. I. Synthesis of 1,2- and 3-dimethoxy-4-methylestratrienes (Abstract only)	Vol/Iss: 20 (2)	Pages: 336-342	Date: 1972	
	51	Author: NUMAZAWA et al. Publ: <u>Steroids</u>	Title: Novel and Regiospecific Synthesis of 2-Amino Estrogens via Zincke Nitration	Vol/Iss: 41 (5)	Pages: 675-682	Date: 1983	
	52	Author: OMAR et al. Publ: <u>European Journal of Medicinal Chemistry</u>	Title: Synthesis, binding affinities and uterotrophic activity of some 2-substituted estradiol and ring-A-fused pyrone derivatives	Vol/Iss: 29	Pages: 25-32	Date: 1994	
	53	Author: PERT et al. Publ: <u>Australian Journal of Chemistry</u>	Title: Preparations of 2,4-disubstituted estradiols (Abstract only)	Vol/Iss: 42 (3)	Pages: 421-432	Date: 1989	
	54	Author: PETERS et al. Publ: <u>Journal of Medicinal Chemistry</u>	Title: 17-Desoxy Estrogen Analogues	Vol/Iss: 32 (7)	Pages: 1642-1652	Date: 1989	
Oct 17 2002 RECEIVED	55	Author: PFEIFFER et al. Publ: <u>Journal of Endocrinology</u>	Title: Are catechol estrogens obligatory mediators of estrogen action in the central nervous system? I. Characterization of pharmacological probes with different receptor binding affinities and catechol estrogen formation rates (Abstract only)	Vol/Iss: 110 (3)	Pages: 489-497	Date: 1986	
	56	Author: SATO et al. Publ: <u>Horm. Carcinog. II. Proceedings Int. Symp., 2nd (1996), Meeting</u> Date 1994	Title: Natural estrogens induce modulation of microtubules in Chinese hamster V79 cells in culture (Abstract only)	Vol/Iss: 110 (3)	Pages: 454-457	Date: 1996	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

TECH CENTER 1600/2900



Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known
Sheet		9	of	10
				Attorney Docket Number
				05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²	
	57	Author: SHISHKINA et al. Publ: <u>Khim.-Farm. Zh.</u>	Title: Synthesis and properties of condensed heterocyclic derivatives of estra-4, 9-dien-17.beta.-ol-3-one (Abstract only)	Vol/Iss: 8 (1)	Pages: 7-11	Date: 1974
	58	Author: SINGH et al. Publ: <u>Molecular and Cellular Endocrinology</u>	Title: Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate (Abstract only)	Vol/Iss: 160 (1-2)	Pages: 61-66	Date: 2000
	59	Author: SIRACUSA et al. Publ: <u>Journal of Embryology and Experimental Morphology</u>	Title: The effect of microtubule- and microfilament-disrupting drugs on preimplantation mouse embryos (Abstract only)	Vol/Iss: 60	Pages: 71-82	Date: 12/1980
	60	Author: SPYRIOUNIS et al. Publ: <u>Arch. Pharm.</u>	Title: Copper (II) complex of an estradiol derivative with potent antiinflammatory properties (Abstract only)	Vol/Iss: 324 (9)	Pages: 533-536	Date: 1991
OCT 17 2002	61	Author: WANG et al. Publ: <u>Shengwu Huaxue Zazhi</u>	Title: Photoaffinity labeling of human placental estradiol 17.beta.-dehydrogenase with 2- and 4-azidoestrone, 2- and 4-azidoestradiol (Abstract only)	Vol/Iss: 8 (6)	Pages: 715-718	Date: 1992
RECEIVED	62	Author: WANG et al. Publ: <u>Journal of Medicinal Chemistry</u>	Title: Synthesis of B-Ring Homologated Estradiol Analogues that Modulate Tubulin Polymerization and Microtubule Stability	Vol/Iss: 43	Pages: 2419-2429	Date: 2000
OCT 17 2002	63	Author: WIESE et al. Publ: <u>Journal of Medicinal Chemistry</u>	Title: Induction of the Estrogen Specific Mitogenic Response of MCF-7 Cells by Selected Analogues of Estradiol-17 β . A 3D QSAR Study	Vol/Iss: 40	Pages: 3659-3669	Date: 1997

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

OCT 15 2002

PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE
SC154

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No. 09/939,208

Filing Date 08/24/2001

First Named Inventor Agoston et al.

Group Art Unit 1616

Examiner Name S. N. Qazi, Ph.D.

Sheet

10

of

10

Attorney Docket Number

05213-0852 (43170-263550)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	64	<p>Author: WURTZ et al.</p> <p>Publ: <u>Journal of Medicinal Chemistry</u></p> <p>Title: Three-Dimensional Models of Estrogen Receptor Ligand Binding Domain Complexes, Based on Related Crystal Structures and Mutational and Structure-Activity Relationship Data</p> <p>Vol/Iss: 41</p> <p>Pages: 1803-1814</p> <p>Date: 1998</p>	

RECEIVED
OCT 17 2002
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.